Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 159

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 159
---
ETS 

 (in thousands, except share and per share amounts)

    December 31,

    December 31,

    2024

    2023

    Assets

    Current assets:

    Cash and cash equivalents
     
    $
    21,351

    $
    15,647

    Short-term investments

    62,267

    91,648

    Prepaid expenses and other current assets

    2,644

    3,212

    Total current assets

    86,262

    110,507

    Long-term investments

    5,021

    27,194

    Other assets, long-term

    804

    1,043

    Total assets
     
    $
    92,087

    $
    138,744

    Liabilities and stockholders’ equity

    Current liabilities:

    Accounts payable
     
    $
    3,317

    $
    2,676

    Accrued compensation

    1,676

    4,018

    Accrued liabilities

    4,454

    6,681

    Other current liabilities

    791

    666

    Options subject to repurchase, short-term

    —

    2

    Total liabilities

    10,238

    14,043

    Commitments and contingencies (Note 7)

    Stockholders’ equity:

    Preferred stock, $0.00001 par value; 10,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at December 31, 2024 and December 31, 2023

    —

    —

    Common stock, $0.00001 par value; 500,000,000 shares authorized at December 31, 2024 and December 31, 2023; 29,919,634 and 29,741,445 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively

    —

    —

    Additional paid-in capital

    287,594

    278,881

    Accumulated other comprehensive gain

    31

    275

    Accumulated deficit

    (205,776
    )

    (154,455
    )